Newsfile Corp
24 Jun 2026, 19:45 UTC · 12w ago
Verdict
Headline leans bearish. We score VIA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
ADMA Biologics is accused of using 'channel stuffing' to artificially inflate the appearance of its revenue.
So whatAllegations of revenue manipulation are severe red flags for investors and typically lead to significant valuation resets.
More negative than 98% of claims this week
A class action lawsuit alleges that ADMA Biologics failed to disclose a related party transaction and lacked adequate internal controls.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Kahn Swick & Foti, LLC has filed a securities lawsuit against ADMA Biologics for losses incurred between August 9, 2024, and March 25, 2026.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities class action following undisclosed growth obstacles and a 70% stock decline.
More negative than 96% of ticker scores this week
The company is facing a class action securities lawsuit alleging fraud, channel stuffing, and lack of internal controls.
More negative than 87% of ticker scores this week
The company is subject to a securities fraud class action regarding alleged anticompetitive agreements and regulatory risks.
More negative than 87% of ticker scores this week
The company is facing a securities fraud class action due to compliance misrepresentations and a 22% stock decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
No price for VIA right now — the quote feed didn't answer.
VIA chart →
